Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
Status:
Recruiting
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this randomized, double-blind, placebo-controlled study is to assess the
efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over
78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the
glucocerebrosidase 1 (GBA1) gene (GBA-PD).